Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02452372 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)
A Phase 1 study, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02452372 is a Phase 1 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT02452372, a Phase 1 study, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of givosiran (ALN-AS1) in AIP patients as well as to characterize pharmacokinetics (PK) and pharmacodynamics (PD) of ALN-AS1 in AIP patients.
Interventions
- DRUG Sterile Normal Saline (0.9% NaCl)
- DRUG givosiran (ALN-AS1)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-05-06 |
| Est. Completion | 2017-09-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02452372
The ClinicalTrials.gov registry entry for NCT02452372 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sterile Normal Saline (0.9% NaCl) is the first listed.
NCT02452372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02452372 about?
NCT02452372 is a clinical study titled "A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)". The purpose of this study is to evaluate the safety and tolerability of givosiran (ALN-AS1) in AIP patients as well as to characterize pharmacokinetics (PK) and pharmacodynamics (PD) of ALN-AS1 in AIP patients.
What is the current status of trial NCT02452372?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2015-05-06. Estimated completion is 2017-09-06.
What interventions are being tested in trial NCT02452372?
The interventions under investigation include: Sterile Normal Saline (0.9% NaCl) (DRUG), givosiran (ALN-AS1) (DRUG).
Who is sponsoring clinical trial NCT02452372?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.